{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T21:43:34Z","timestamp":1780955014409,"version":"3.54.1"},"reference-count":34,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2011,3,22]],"date-time":"2011-03-22T00:00:00Z","timestamp":1300752000000},"content-version":"vor","delay-in-days":21,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Internal Medicine Journal"],"published-print":{"date-parts":[[2011,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background:\u2002<\/jats:bold> Several cellular pathways are implicated in the pathogenesis of pulmonary arterial hypertension (PAH) and attempts to arrest disease progression with a single drug would not be expected to succeed in the medium term. In clinical practice, combination therapy is often used in patients deteriorating on monotherapy, despite the absence of firm evidence from randomized controlled controls.<\/jats:p><jats:p><jats:bold>Methods:\u2002<\/jats:bold> From January 2005 to August 2009, 112 patients with World Health Organisation Functional Class (FC) II\u2013IV PAH deteriorating on monotherapy received non\u2010parenteral combination therapy at six Australian PAH expert hospitals. Combination therapy included bosentan, sitaxentan, ambrisentan, iloprost and sildenafil. Data were prospectively collected for survival status, 6\u2010min walk distance, FC and echocardiographic parameters at the start of monotherapy through to commencement of combination therapy and at 6\u2010monthly intervals thereafter.<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> After varying periods of monotherapy (18.7\u2003\u00b1\u200313.4\u2003months), survival estimates on combination therapy were 88%, 71% and 61% for the additional 1, 2 and 3\u2003years respectively. Survival on dual therapy in patients with idiopathic PAH\/familial PAH was 93% at 1\u2003year and 79% at 2\u2003years, and for scleroderma\u2010related PAH, 72% at 1\u2003year and 48% at year 2 after initiation of combination therapy. In survivors, dual therapy reversed the deterioration in FC, from 3.1\u2003\u00b1\u20030.6 on monotherapy to 2.2\u2003\u00b1\u20030.6 at 12\u2003months. Similarly, dual therapy improved 6\u2010min walk distance from 316\u2003\u00b1\u2003119\u2003m to 406\u2003\u00b1\u2003129\u2003m at 12\u2003months, and sequential echocardiography demonstrated a fall in pulmonary artery systolic pressure and improved right ventricular function.<\/jats:p><jats:p><jats:bold>Conclusions:\u2002<\/jats:bold> Dual non\u2010parenteral therapy appears safe and effective and should be considered for PAH patients who are deteriorating on monotherapy to improve long\u2010term outcomes.<\/jats:p>","DOI":"10.1111\/j.1445-5994.2010.02403.x","type":"journal-article","created":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T09:39:44Z","timestamp":1291196384000},"page":"235-244","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Survival after the initiation of combination therapy in patients with pulmonary arterial hypertension: an Australian collaborative report"],"prefix":"10.1111","volume":"41","author":[{"given":"A.","family":"Keogh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Strange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Kotlyar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Kilpatrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Macdonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Pidoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Kermeen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Steele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Dalton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Gabbay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,3,22]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1136\/thx.2007.090480","article-title":"Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland","volume":"63","author":"JSR for the National Pulmonary Hypertension Centres of the UK and Ireland","year":"2008","journal-title":"Thorax"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-200302000-00019"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.6.8.1337"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050010"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(02)02012-0"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.05.00075305"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi283"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.03.00054103"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.04.017"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2004.02.037"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.911818"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.110.963983"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehp022"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2009.11.028"},{"key":"e_1_2_7_16_2","unstructured":"Australian Government. Department of Health and Ageing.Schedule of pharmaceutical benefits.2009[cited 2009 Feb 18]. Available from URL:http:\/\/www.pbs.gov.au"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-149-8-200810210-00004"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(03)00555-2"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.smj.0000217927.81107.65"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1155\/2008\/897102"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.04.00051104"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.03.00008003"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00081706"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.06.00057906"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012212"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020204"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.05.00054804"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi728"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2005.069484"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-115-5-343"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00072709"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2261-10-9"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.102.8.865"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejheart.2004.12.011"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2007.01.001"}],"container-title":["Internal Medicine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1445-5994.2010.02403.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1445-5994.2010.02403.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T09:54:35Z","timestamp":1697363675000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1445-5994.2010.02403.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["10.1111\/j.1445-5994.2010.02403.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1445-5994.2010.02403.x","archive":["Portico"],"relation":{},"ISSN":["1444-0903","1445-5994"],"issn-type":[{"value":"1444-0903","type":"print"},{"value":"1445-5994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3]]},"assertion":[{"value":"2011-03-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}